Mr. Cashman: SANUWAVE is an emerging leader in the regenerative medicine category, utilizing high-energy pressure waves delivered in the shockwave spectrum. The shockwaves elicit a biological response, resulting in the release of angiogenic growth factors and ultimate new blood vessel formation. This process helps the body get back to a normal healing response for tissue or bone regeneration. The SANUWAVE platform was formed in August of 2005 via a divestiture by HealthTronics, who is the leader in urology and lithotripsy - breaking up kidney stones using shockwaves - services here in the U.S. Through the divestiture, we acquired all of the intellectual property, 50-plus worldwide and a legacy, global orthopedic product line. We're really focused in four areas today. We had a longstanding history in orthopedics, with two FDA Class III-approved indications, which is the highest-regulated FDA approval pathway - one for heel pain and one for elbow pain. Once I became involved, we built on this legacy and know-how with the development of next-generation devices for orthopedics, and have expanded our interests into wound care, plastic, and cosmetic procedures and cardiac, for which we just filed some new, provisional patents for methods breaking up plaque and increasing vascularity in compromised heart muscle. Our major focus is in our lead product, dermaPACEª. dermaPACE is addressing the advanced wound care market, which we define as about a $5 billion opportunity in the U.S. dermaPACE is already approved in Europe and has the European Community's CE mark. And we are currently pursuing our first clinical indication in the U.S. for diabetic foot ulcers (DFU), for which we expect to complete enrollment in the first quarter of 2010.
Tickers included in this excerpt: SNWV.OB
For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.